S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
A gold storm is coming… (Ad)
Europe bans Russian diesel, other oil products over Ukraine
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
Gas prices dip in NJ, around nation as cold weather returns
How will EU ban and West's price cap on Russian diesel work?
NASDAQ:ERYP

ERYTECH Pharma - ERYP Stock Forecast, Price & News

$1.20
-0.08 (-6.25%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.08
▼
$1.30
50-Day Range
$0.33
▼
$1.38
52-Week Range
$0.30
▼
$2.18
Volume
39,969 shs
Average Volume
83,314 shs
Market Capitalization
$37.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ERYTECH Pharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of ERYTECH Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.93) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.78 out of 5 stars

Medical Sector

1027th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

168th out of 168 stocks

See Top Rated MarketRank™ Stocks Here
ERYP stock logo

About ERYTECH Pharma (NASDAQ:ERYP) Stock

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Receive ERYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

ERYP Stock News Headlines

February 1, 2023 | msn.com
Telecoms, Natural Resources Lead European Equities Lower in Wednesday Trading
January 30, 2023 | msn.com
European Equities Start the Week Modestly Higher Amid German GDP Contraction
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 20, 2023 | msn.com
European Equities Nudge Lower in Friday Trading, With ADRs Ending Week Flat
January 9, 2023 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022
December 27, 2022 | msn.com
European Equities Broadly Flat Amid End of Chinese COVID-19 Quarantine Restrictions
December 21, 2022 | msn.com
European Equities Follow US Markets Higher in Wednesday Trading
December 17, 2022 | msn.com
European Equities Sharply Lower With Pharma, Telecoms Most Active Sectors
February 5, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 6, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _November 30, 2022
December 6, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022
November 21, 2022 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
November 21, 2022 | finance.yahoo.com
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
November 15, 2022 | msn.com
European Markets Move Higher Helped by Upbeat US Inflation Data
November 11, 2022 | msn.com
European ADRs Move Slightly Lower in Friday Trading
November 8, 2022 | msn.com
European ADRs Move Higher in Tuesday Trading, Adding to Monday's Gains
November 2, 2022 | msn.com
European ADRs Nudge Lower in Wednesday Trading
October 21, 2022 | seekingalpha.com
ERYP ERYTECH Pharma S.A.
October 13, 2022 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH Announces Receipt of Nasdaq Notice
October 13, 2022 | finance.yahoo.com
ERYTECH Announces Receipt of Nasdaq Notice
October 10, 2022 | msn.com
European ADRs Move Lower in Monday Trading
October 5, 2022 | finance.yahoo.com
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
October 4, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022
September 12, 2022 | finanznachrichten.de
Erytech Pharma S.A.: ERYTECH Provides Business and Financial Update for the First Half of 2022
September 12, 2022 | finance.yahoo.com
ERYTECH Provides Business and Financial Update for the First Half of 2022
September 6, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022
September 6, 2022 | finance.yahoo.com
Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022
See More Headlines
Receive ERYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

ERYP Company Calendar

Today
2/05/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ERYP
CUSIP
N/A
CIK
1624422
Web
www.erytech.com
Phone
(347) 874-4438
Fax
33-4-78-75-56-29
Employees
196
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.57
Current Ratio
2.25
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$4.95 million
Price / Sales
7.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.87 per share
Price / Book
1.38

Miscellaneous

Outstanding Shares
31,020,000
Free Float
30,417,000
Market Cap
$37.23 million
Optionable
Not Optionable
Beta
2.64

Key Executives

  • Gil Beyen
    Chief Executive Officer & Director
  • Eric Soyer
    Chief Operating & Financial Officer
  • Stewart Craig
    Chief Technical Officer
  • Iman El-Hariry
    Chief Medical Officer
  • Jérôme Bailly
    Chief Quality Officer & Deputy General Manager

Key Competitors

View All Competitors













ERYP Stock - Frequently Asked Questions

How have ERYP shares performed in 2023?

ERYTECH Pharma's stock was trading at $0.3301 at the beginning of the year. Since then, ERYP stock has increased by 263.6% and is now trading at $1.2001.
View the best growth stocks for 2023 here.

When is ERYTECH Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our ERYP earnings forecast.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD).

When did ERYTECH Pharma IPO?

(ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What is ERYTECH Pharma's stock symbol?

ERYTECH Pharma trades on the NASDAQ under the ticker symbol "ERYP."

Who are ERYTECH Pharma's major shareholders?

ERYTECH Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ERYTECH Pharma?

Shares of ERYP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ERYTECH Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $1.20.

How much money does ERYTECH Pharma make?

ERYTECH Pharma (NASDAQ:ERYP) has a market capitalization of $37.23 million and generates $4.95 million in revenue each year.

How many employees does ERYTECH Pharma have?

The company employs 196 workers across the globe.

How can I contact ERYTECH Pharma?

ERYTECH Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The official website for the company is www.erytech.com. The company can be reached via phone at (347) 874-4438, via email at investors@erytech.com, or via fax at 33-4-78-75-56-29.

This page (NASDAQ:ERYP) was last updated on 2/5/2023 by MarketBeat.com Staff